Axel R. Hanauske

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Éric Raymond, Jérôme Alexandre, Sandrine Faivre et al. · Journal of Clinical Oncology · 2004 · 500 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma

Jacek Jassem, Rodryg Ramlau, Armando Santoro et al. · Journal of Clinical Oncology · 2008 · 231 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors

Cees J. van Groeningen, Godefridus J. Peters, Jan H. Schornagel et al. · Journal of Clinical Oncology · 2000 · 158 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +14

Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group

Evangelos Briasoulis, Ian Judson, Nicholas Pavlidis et al. · Journal of Clinical Oncology · 2000 · 60 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association with Molecular Target Expression

Henry Gómez, Sergio Santillana, Carlos Vallejos et al. · Clinical Cancer Research · 2006 · 58 citations

Medicine, Oncology, Pharmacology +11